Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
Open Forum Infectious Diseases, Volume 9, No. 11, Article ofac565, Year 2022
Notification
URL copied to clipboard!
There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were hospitalized or died. The 43% observed risk reduction with bebtelovimab was not statistically significant (P = 0.14).